|
|
|
|
|
| CUSIP No. 58406B103 |
|
13D |
|
Page 10 of 13 pages |
| Item 5. |
Interest in Securities of the Issuer. |
Item 5 of the Schedule 13D is amended and restated in its entirety as follows:
(a) – (b)
The following sets forth, as of
the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has
the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, based on 80,523,932 shares of Common Stock
outstanding as of May 5, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 18, 2023:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reporting Person |
|
Amount
beneficially
owned |
|
|
Percent
of class |
|
|
Sole
power to
vote or to
direct the
vote |
|
|
Shared
power to
vote or to
direct the
vote |
|
|
Sole power
to dispose
or to direct
the
disposition |
|
|
Shared
power to
dispose or to
direct the
disposition |
|
| Ally Bridge Group-WTT Global Life Science Capital
Partners, L.P. |
|
|
34,237,606 |
|
|
|
34.3 |
% |
|
|
0 |
|
|
|
34,237,606 |
|
|
|
0 |
|
|
|
34,237,606 |
|
| ABG-WTT Global Life Science Capital Partners GP,
L.P. |
|
|
34,237,606 |
|
|
|
34.3 |
% |
|
|
0 |
|
|
|
34,237,606 |
|
|
|
0 |
|
|
|
34,237,606 |
|
| ABG-WTT Global Life Science Capital Partners GP
Limited |
|
|
34,237,606 |
|
|
|
34.3 |
% |
|
|
0 |
|
|
|
34,237,606 |
|
|
|
0 |
|
|
|
34,237,606 |
|
| Ally Bridge MedAlpha Master Fund L.P. |
|
|
9,312,215 |
|
|
|
11.1 |
% |
|
|
0 |
|
|
|
9,312,215 |
|
|
|
0 |
|
|
|
9,312,215 |
|
| Ally Bridge Group (NY) LLC |
|
|
9,312,215 |
|
|
|
11.1 |
% |
|
|
0 |
|
|
|
9,312,215 |
|
|
|
0 |
|
|
|
9,312,215 |
|
| ABG Management Ltd. |
|
|
9,312,215 |
|
|
|
11.1 |
% |
|
|
0 |
|
|
|
9,312,215 |
|
|
|
0 |
|
|
|
9,312,215 |
|
| ABG WTT-MedAvail Limited |
|
|
34,237,606 |
|
|
|
34.3 |
% |
|
|
0 |
|
|
|
34,237,606 |
|
|
|
0 |
|
|
|
34,237,606 |
|
| Fan Yu |
|
|
9,312,215 |
|
|
|
11.1 |
% |
|
|
0 |
|
|
|
9,312,215 |
|
|
|
0 |
|
|
|
9,312,215 |
|
ABG WTT is the record holder of 15,029,480 shares of Common Stock and may be deemed the beneficial owner of
(i) 5,571,764 shares of Common Stock subject to the Warrants, (ii) 6,818,181 shares of Common Stock subject to the Pre-Funded Warrants and (iii) 6,818,181 shares of Common Stock subject to the Series A
Warrants. MedAlpha is the record holder of 5,894,897 shares of Common Stock and may be deemed the beneficial owner of (i) 1,487,058 shares of Common Stock subject to the Warrants, (ii) 965,130 shares of Common Stock subject to the Pre-Funded Warrants and (iii) 965,130 shares of Common Stock subject to the Series A Warrants.
ABG WTT
is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee
of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general
partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG WTT. Each of them
disclaims any such beneficial ownership.